ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

NSI Stem Cell Launches New Multiple Sclerosis and Parkinson’s Disease Treatments

Adipose stem cells offer far-reaching potential in treatment of chronic conditions, publishes nsistemcell.com

NSI Stem Cell Launches New Multiple Sclerosis and Parkinson’s Disease Treatments

Brandon, Florida - November 30, 2016 /MarketersMedia/

According to reports from The Multiple Sclerosis Foundation, an estimated 2.5 million people suffer from MS globally with 200 new cases diagnosed each week in the United States alone. Studies show Parkinson's disease afflicts approximately 1 million across the nation with 60,000 new cases arising annually. With this surging prevalence in mind, a spokesperson for NSI Stem Cell has launched a new type of treatment for those affected by these and a number of other chronic conditions.

Said the spokesperson, "Until fairly recently, patients have found limited relief with many of the traditional treatments available to them. Science has made significant strides in stem cell therapy over the last several years, opening up an array of new opportunities for all those individuals suffering from chronic medical conditions. We've successfully treated a variety of issues using adipose stem cells, and we're proud to extend our treatments to those with MS and Parkinson's disease."

Adipose stem cells are taken from adult fatty tissue, typically that of the abdomen or above the superior iliac spine. When compared to retrieval from bone marrow, the process of gathering adipose stem cells is considerably less invasive. Research indicates these are also up to 500 percent more potent than their counterparts. Once removed from fatty tissues, these cells are relocated to areas of the body in which they are needed.

Stem cells have been the target of numerous medical studies for more than three decades. During the early 1980's, scientists discovered such cells held properties unlike others. Having not yet developed specific structures and functions, they have the capacity to regenerate blood as well as muscle, nerve and organ tissues. In the case of Stem cell therapy for ms, they are used to regenerate nerves as well as their protective coverings known as myelin sheaths. When combating Parkinson's disease, stem cells are used in the reconstruction of dopamine-producing cells in the brain.

Concluded the clinic's spokesperson, "Patients undergoing our stem cell for copd treatments have experienced greater lung capacity and a reduction of mucous and phlegm as well as improvements in other symptoms accompanying the condition. We're also treating diabetes, ALS, back and joint problems, neuropathy, spinal cord injuries and a range of other issues thanks to breakthroughs in the medical community. Research is ongoing, and we will continue to offer new therapies as they become available. We're proud to offer these services to patients and eagerly await future advancements."

About NSI Stem Cell:

NSI Stem Cell is a stem cell therapy center and clinic with four locations throughout Florida. Using revolutionary procedures, their team successfully treats patients with chronic and debilitating conditions who have found little relief through other methods.

For more information, please visit https://nsistemcell.com/

Contact Info:
Name: NSI Stem Cell
Organization: NSI Stem Cell
Phone: (877) 278-3623

Source: http://marketersmedia.com/nsi-stem-cell-launches-new-multiple-sclerosis-and-parkinsons-disease-treatments/150974

Release ID: 150974

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.